{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:54:35Z","timestamp":1777701275724,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Interferon &amp; Cytokine Research"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:p>\n                    Low-dose oral interferon could exert immune-modulating effects in human. We conducted a clinical trial to investigate the efficacy of oral interferon-alpha in preventing hepatitis C relapse. Totally 169 genotype 1b chronic hepatitis C patients having achieved end-of-therapy virological clearance were randomized to receive interferon-alpha lozenge 500\u2009IU\/day (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    =59), 1,500\u2009IU\/day (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    =53), or placebo (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    =57) for 24 weeks. Overall, no significant differences were found for the relapse rates in the 3 groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &gt;0.05). However, in patients with fibroindex 1.4\u20131.7, relapse occurred in 1\/12 (8.3%) 500\u2009IU-group patients versus 9\/21 (42.9%) patients of the other groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.05). In 158 patients receiving at least 4 weeks of oral interferon, significantly higher platelet count was found at the end of trial in the 500\u2009IU group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.003). In thrombocytopenic patients, a significantly expedited recovery of platelet count was found in the 500\u2009IU group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.002). No drug-related severe adverse events were reported. In conclusion, at 500\u2009IU\/day, oral interferon exerted a borderline suppression effect of virological relapse in chronic hepatitis C patients with mild liver fibrosis. Additionally, it significantly expedited platelet count recovery after the end of peginterferon therapy.\n                  <\/jats:p>","DOI":"10.1089\/jir.2013.0074","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T09:33:46Z","timestamp":1384508026000},"page":"187-194","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A Double-Blind Randomized Controlled Study to Evaluate the Efficacy of Low-Dose Oral Interferon-Alpha in Preventing Hepatitis C Relapse"],"prefix":"10.1177","volume":"34","author":[{"given":"Chuan-Mo","family":"Lee","sequence":"first","affiliation":[{"name":"Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Chiayi Christian Hospital","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[{"name":"Keelung Chang Gung Memorial Hospital","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Chih","family":"Tseng","sequence":"additional","affiliation":[{"name":"Tzuchi University","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[{"name":"China Medical University Hospital","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shui-Yi","family":"Tung","sequence":"additional","affiliation":[{"name":"Chiayi Chang Gung Memorial Hospital","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Jen","family":"Fang","sequence":"additional","affiliation":[{"name":"Show-Chwan Memorial Hospital","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Taipei Veterans General Hospital and Institute of Clinical Medicine","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[{"name":"Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[{"name":"Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Jang","family":"Tsai","sequence":"additional","affiliation":[{"name":"Chiayi Christian Hospital","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Chung","family":"Fang","sequence":"additional","affiliation":[{"name":"Chiayi Christian Hospital","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Wei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Chang Gung University","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau-Ting","family":"Yeh","sequence":"additional","affiliation":[{"name":"Chang Gung University","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"e_1_3_3_2_1","first-page":"213","article-title":"An interim report on the effect of natural human interferon alpha (IFN-alpha) lozenges in patients seropositive for the human immunodeficiency virus type 1 (HIV-1)","volume":"41","author":"Babiuch L","year":"1993","unstructured":"Babiuch L, , Mian M, , Kami\u0144ska E, , Szyma\u0144ska B, , Georgiades JA. 1993. An interim report on the effect of natural human interferon alpha (IFN-alpha) lozenges in patients seropositive for the human immunodeficiency virus type 1 (HIV-1). Arch Immunol Ther Exp (Warsz), 41:213\u2013219.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"e_1_3_3_3_1","first-page":"221","article-title":"Evaluation of the efficacy of natural human interferon alpha lozenges on the clinical course of childhood neoplasia and in chronic hepatitis B virus infection in patients who were successfully treated for pediatric malignancies","volume":"41","author":"Balcerska A","year":"1993","unstructured":"Balcerska A, , Bohdan Z, , Drozy\u0144ska E, , Kozielska E, , Szarszewski A, , Georgiades JA. 1993. Evaluation of the efficacy of natural human interferon alpha lozenges on the clinical course of childhood neoplasia and in chronic hepatitis B virus infection in patients who were successfully treated for pediatric malignancies. Arch Immunol Ther Exp (Warsz), 41:221\u2013227.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1997.17.625"},{"key":"e_1_3_3_5_1","first-page":"229","article-title":"Treatment of chronic viral hepatitis type B with oral mucosal administration of natural human interferon alpha lozenges","volume":"41","author":"Caban J","year":"1993","unstructured":"Caban J, , Mossor-Ostrowska J, , Zyrkowska-Bieda T, , Zejc M, , Janas-Skulina U, , Cie\u015bla A, , Cummins JM, , Georgiades JA. 1993. Treatment of chronic viral hepatitis type B with oral mucosal administration of natural human interferon alpha lozenges. Arch Immunol Ther Exp (Warsz), 41:229\u2013235.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"e_1_3_3_6_1","first-page":"243","article-title":"Hepatitis C virus therapy update 2013","volume":"29","author":"Casey LC","year":"2013","unstructured":"Casey LC, , Lee WM. 2013. Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol, 29:243\u2013249.","journal-title":"Curr Opin Gastroenterol"},{"key":"e_1_3_3_7_1","first-page":"193","article-title":"Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus","volume":"41","author":"Cummins JM","year":"1993","unstructured":"Cummins JM, , Hutcheson DP, , Cummins MJ, , Georgiades JA, , Richards AB. 1993. Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch Immunol Ther Exp, 41:193\u2013197.","journal-title":"Arch Immunol Ther Exp"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.2005.66.164"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1987.7.553"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-201-43499"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1998.18.17"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/107999099313433"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92671-7"},{"key":"e_1_3_3_15_1","first-page":"160","article-title":"Chronic recurrent aphthous stomatitis: oral treatment with low-dose interferon alpha","volume":"2","author":"Hutchinson VA","year":"1990","unstructured":"Hutchinson VA, , Angenend JL, , Mok WL, , Cummins JM, , Richards AB. 1990. Chronic recurrent aphthous stomatitis: oral treatment with low-dose interferon alpha. Mol Biother, 2:160\u2013164.","journal-title":"Mol Biother"},{"key":"e_1_3_3_16_1","first-page":"257","article-title":"Three open-label studies of oral interferon alpha in the treatment of HIV disease","volume":"86","author":"Jordan WC","year":"1994","unstructured":"Jordan WC. 1994. Three open-label studies of oral interferon alpha in the treatment of HIV disease. J Natl Med Assoc, 86:257\u2013262.","journal-title":"J Natl Med Assoc"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21520"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_3_3_19_1","first-page":"211","article-title":"Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha","volume":"2","author":"Lecce JG","year":"1990","unstructured":"Lecce JG, , Cummins JM, , Richards AB. 1990. Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. Mol Biother, 2:211\u2013216.","journal-title":"Mol Biother"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1998.18.647"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04269.x"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.9.5633"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00005"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/019262338801600208"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-S2-S3"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00970.x"},{"key":"e_1_3_3_27_1","first-page":"237","article-title":"Observation of the effect of low oral doses of human leukocytic interferon alpha in children with chronic HBV infection and impaired immune response","volume":"41","author":"Ratajczak B","year":"1993","unstructured":"Ratajczak B. 1993. Observation of the effect of low oral doses of human leukocytic interferon alpha in children with chronic HBV infection and impaired immune response. Arch Immunol Ther Exp, 41:237\u2013240.","journal-title":"Arch Immunol Ther Exp"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1089\/107999099313514"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.176.4041.1326"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1998.18.255"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/107999099313497"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12028"},{"key":"e_1_3_3_33_1","first-page":"24","article-title":"Improved survival of four cats infected with feline leukemia virus after oral administration of interferon","volume":"17","author":"Steed VP","year":"1987","unstructured":"Steed VP. 1987. Improved survival of four cats infected with feline leukemia virus after oral administration of interferon. Feline Pract, 17:24\u201330.","journal-title":"Feline Pract"},{"key":"e_1_3_3_34_1","first-page":"6","article-title":"Response of feline leukemia virus-induced nonregenerative anemia to oral administration of an interferon containing preparation","volume":"12","author":"Tompkins MB","year":"1982","unstructured":"Tompkins MB, , Cummins JM. 1982. Response of feline leukemia virus-induced nonregenerative anemia to oral administration of an interferon containing preparation. Feline Pract, 12:6\u201315.","journal-title":"Feline Pract"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.1991.199.10.1477"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182000063241"},{"key":"e_1_3_3_37_1","first-page":"241","article-title":"Treatment of fourteen chronic active HBsAg+, HBeAg+ hepatitis patients with low dose natural human interferon alpha administered orally","volume":"41","author":"Zieli\u0144ska W","year":"1993","unstructured":"Zieli\u0144ska W, , Paszkiewicz J, , Korczak A, , W\u0142asiuk M, , Z\u00f3\u0142towska A, , Szutowicz A, , Cummins JM, , Georgiades JA. 1993a. Treatment of fourteen chronic active HBsAg+, HBeAg+ hepatitis patients with low dose natural human interferon alpha administered orally. Arch Immunol Ther Exp (Warsz), 41:241\u2013251.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"e_1_3_3_38_1","first-page":"253","article-title":"Treatment of six patients with chronic active HCV hepatitis, with low dose natural human interferon alpha administered orally","volume":"41","author":"Zieli\u0144ska W","year":"1993","unstructured":"Zieli\u0144ska W, , Paszkiewicz J, , Korczak A, , W\u0142asiuk M, , Z\u00f3\u0142towska A, , Szutowicz A, , Cummins JM, , Georgiades JA. 1993b. Treatment of six patients with chronic active HCV hepatitis, with low dose natural human interferon alpha administered orally. Arch Immunol Ther Exp (Warsz), 41:253\u2013257.","journal-title":"Arch Immunol Ther Exp (Warsz)"}],"container-title":["Journal of Interferon &amp; Cytokine Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jir.2013.0074","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jir.2013.0074","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jir.2013.0074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:32:55Z","timestamp":1777455175000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jir.2013.0074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1089\/jir.2013.0074"],"URL":"https:\/\/doi.org\/10.1089\/jir.2013.0074","relation":{},"ISSN":["1079-9907","1557-7465"],"issn-type":[{"value":"1079-9907","type":"print"},{"value":"1557-7465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}